{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T11:19:28Z","timestamp":1773832768854,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2009,3,20]],"date-time":"2009-03-20T00:00:00Z","timestamp":1237507200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1007\/s00774-009-0055-9","type":"journal-article","created":{"date-parts":[[2009,3,19]],"date-time":"2009-03-19T01:52:12Z","timestamp":1237427532000},"page":"464-470","source":"Crossref","is-referenced-by-count":18,"title":["The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study"],"prefix":"10.1007","volume":"27","author":[{"given":"Umit","family":"Dundar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vural","family":"Kavuncu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ihsan H.","family":"Ciftci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deniz","family":"Evcik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozlem","family":"Solak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuncay","family":"Cakir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,3,20]]},"reference":[{"key":"55_CR1","doi-asserted-by":"crossref","first-page":"5134","DOI":"10.1073\/pnas.88.12.5134","volume":"88","author":"R Pacifici","year":"1991","unstructured":"Pacifici R, Brown C, Puscheck E, Friedrich E, Slatopolsky E, Maggio D, Mccracken R, Avioli LV (1991) Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc Natl Acad Sci 88:5134\u20135138","journal-title":"Proc Natl Acad Sci"},{"key":"55_CR2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1210\/edrv.23.3.0465","volume":"23","author":"BL Riggs","year":"2002","unstructured":"Riggs BL, Khosla S, Melton LJ (2002) Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 23:279\u2013302","journal-title":"Endocr Rev"},{"key":"55_CR3","doi-asserted-by":"crossref","unstructured":"Khosla S, Melton LJ, Riggs BL (2002) Estrogen and the male skeleton. J Clin Endocrinol Metab 87:1443\u20131450","DOI":"10.1210\/jcem.87.4.8417"},{"key":"55_CR4","first-page":"115","volume":"21","author":"SC Manolagas","year":"2000","unstructured":"Manolagas SC (2000) Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21:115\u2013137","journal-title":"Endocr Rev"},{"key":"55_CR5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/BF00217561","volume":"240","author":"G Morel","year":"1985","unstructured":"Morel G, Boivin G, David L, Dubois PM, Meunier PJ (1985) Immunocytochemical evidence for endogenous calcitonin and parathyroid hormone in osteoblasts from the calvaria of neonatal mice. Absence of endogenous estradiol and estradiol receptors. Cell Tissue Res 240:89\u201393","journal-title":"Cell Tissue Res"},{"key":"55_CR6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/jbmr.5650080108","volume":"8","author":"FG Hustmyer","year":"1993","unstructured":"Hustmyer FG, Walker E, Yu XP, Girasole G, Sakagami Y, Peacock M, Manolagas SC (1993) Cytokine production and surface antigen expression by peripheral blood mononuclear cells in postmenopausal osteoporosis. J Bone Miner Res 8:51\u201359","journal-title":"J Bone Miner Res"},{"key":"55_CR7","doi-asserted-by":"crossref","unstructured":"Pacifici, R (1996) Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 11:1043\u20131051","DOI":"10.1002\/jbmr.5650110802"},{"key":"55_CR8","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1172\/JCI200317215","volume":"111","author":"G Eghbali-Fatourechi","year":"2003","unstructured":"Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL (2003) Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 111:1221\u20131230","journal-title":"J Clin Invest"},{"key":"55_CR9","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","volume":"95","author":"H Yasuda","year":"1998","unstructured":"Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL. Proc Natl Acad Sci 95:3597\u20133602","journal-title":"Proc Natl Acad Sci"},{"key":"55_CR10","doi-asserted-by":"crossref","first-page":"5441","DOI":"10.1210\/en.2003-0717","volume":"144","author":"M Nakamura","year":"2003","unstructured":"Nakamura M, Udagawa N, Matsuura S, Mogi M, Nakamura H, Horiuchi H, Saito N, Hiraoka BY, Kobayashi Y, Takaoka K, Ozawa H, Miyazawa H, Takahashi N (2003) Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology 144:5441\u20135449","journal-title":"Endocrinology"},{"key":"55_CR11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1359\/jbmr.2000.15.1.2","volume":"15","author":"LC Hofbauer","year":"2000","unstructured":"Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL (2000) The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15:2\u201312","journal-title":"J Bone Miner Res"},{"key":"55_CR12","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/35046196","volume":"408","author":"JR Arron","year":"2000","unstructured":"Arron JR, Choi Y (2000) Bone versus immune system. Nature 408:535\u2013536","journal-title":"Nature"},{"key":"55_CR13","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","volume":"12","author":"N Bucay","year":"1998","unstructured":"Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260\u20131268","journal-title":"Genes Dev"},{"key":"55_CR14","first-page":"2061","volume":"86","author":"MJ Rogers","year":"2000","unstructured":"Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88:2961\u20132978","journal-title":"Cancer"},{"key":"55_CR15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.14712\/fb2007053040143","volume":"53","author":"L Sefc","year":"2007","unstructured":"Sefc L, Broulik P, Pelichovska T, Necas E (2007) Risedronate has no adverse effects on mouse haematopoiesis. Folia Biologica (Praha) 53:143\u2013145","journal-title":"Folia Biologica (Praha)"},{"key":"55_CR16","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650090802","volume":"9","author":"JA Kanis","year":"1994","unstructured":"Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khaltaev N (1994) The diagnosis of osteoporosis. J Bone Miner Res 9:1137\u20131141","journal-title":"J Bone Miner Res"},{"key":"55_CR17","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","volume":"423","author":"WJ Boyle","year":"2003","unstructured":"Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337\u2013342","journal-title":"Nature"},{"key":"55_CR18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.5507\/bp.2001.013","volume":"145","author":"D Stejskal","year":"2001","unstructured":"Stejskal D, Bartek J, Pastorkova R, Ruzicka V, Oral I, Horalik D (2001) Osteoprotegerin, RANK, RANKL. Biomed Pap 145:61\u201364","journal-title":"Biomed Pap"},{"key":"55_CR19","doi-asserted-by":"crossref","first-page":"41155","DOI":"10.1074\/jbc.M506366200","volume":"280","author":"LA Schneeweis","year":"2005","unstructured":"Schneeweis LA, Willard D, Milla ME (2005) Functional dissection of osteoprotegerin and its interaction with receptor activator of NF-kappaB ligand. J Biol Chem 280:41155\u201341164","journal-title":"J Biol Chem"},{"key":"55_CR20","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/j.bios.2004.08.018","volume":"20","author":"P Skladala","year":"2005","unstructured":"Skladala P, Jilkova Z, Svoboda I, Kolar V (2005) Investigation of osteoprotegerin interactions with ligands and antibodies using piezoelectric biosensors. Biosens and Bioelectron 20:2027\u20132034","journal-title":"Biosens and Bioelectron"},{"key":"55_CR21","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00198-005-0035-4","volume":"17","author":"H Dobnig","year":"2006","unstructured":"Dobnig H, Hofbauer LC, Viereck V, Obermayer-Pietsch B, Fahrleitner-Pammer A (2006) Changes in the RANK ligand\/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporos Int 17:693\u2013703","journal-title":"Osteoporos Int"},{"key":"55_CR22","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1055\/s-2008-1046787","volume":"40","author":"AD Anastasilakis","year":"2008","unstructured":"Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Koukoulis G, Kita M, Avramidis A (2008) Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial. Horm Metab Res 40:281\u2013285","journal-title":"Horm Metab Res"},{"key":"55_CR23","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1530\/eje.0.1480527","volume":"148","author":"H Valleala","year":"2003","unstructured":"Valleala H, Mandelin J, Laasonen L, Koivula M, Risteli J, Konttinen Y (2003) Effect of cyclical intermittent etidronate therapy on circulating osteoprotegerin levels in patients with rheumatoid arthritis. Eur J Endocrinol 148:527\u2013530","journal-title":"Eur J Endocrinol"},{"key":"55_CR24","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/art.10834","volume":"48","author":"L Alvarez","year":"2003","unstructured":"Alvarez L, Peris P, Guanabens N, Vidal S, Ros I, Pons F, Filella X, Monegal A, Munoz-Gomez J, Ballesta A (2003) Serum osteoprotegerin and its ligand in Paget\u2019s disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. Arthritis Rheum 48:824\u2013828","journal-title":"Arthritis Rheum"},{"key":"55_CR25","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1359\/jbmr.2004.19.1.147","volume":"19","author":"B Pan","year":"2004","unstructured":"Pan B, Farrugia AN, To LB, Findlay DM, Green J, Lynch K, Zannettino AC (2004) The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). J Bone Miner Res 19:147\u2013154","journal-title":"J Bone Miner Res"},{"key":"55_CR26","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.bone.2006.08.003","volume":"40","author":"G Martini","year":"2007","unstructured":"Martini G, Gennari L, Merlotti D, Salvadori S, Franci M, Campagna S, Avanzati A, De Paola V, Valleggi F, Nuti R (2007) Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget\u2019s disease of bone. Bone 40:457\u2013463","journal-title":"Bone"},{"key":"55_CR27","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1006\/bbrc.2002.6510","volume":"291","author":"V Viereck","year":"2002","unstructured":"Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Gr\u00fcndker C, Hofbauer LC (2002) Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 291:680\u2013686","journal-title":"Biochem Biophys Res Commun"},{"key":"55_CR28","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1054\/bjoc.2000.1679","volume":"84","author":"PS Mackie","year":"2001","unstructured":"Mackie PS, Fisher JL, Zhou H, Choong PF (2001) Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br J Cancer 84:951\u2013958","journal-title":"Br J Cancer"},{"key":"55_CR29","first-page":"357","volume":"74","author":"I Nakamura","year":"2006","unstructured":"Nakamura I, Jimi E (2006) Regulation of osteoclast differentiation and function by interleukin-1. Viman Horm 74:357\u2013370","journal-title":"Viman Horm"},{"key":"55_CR30","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1172\/JCI11176","volume":"106","author":"J Lam","year":"2000","unstructured":"Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL (2000) TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 106:1481\u20131488","journal-title":"J Clin Invest"},{"key":"55_CR31","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1172\/JCI200523394","volume":"115","author":"S Wei","year":"2005","unstructured":"Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL (2005) IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 115:282\u2013290","journal-title":"J Clin Invest"},{"key":"55_CR32","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00774-004-0526-y","volume":"22","author":"HA Papadaki","year":"2004","unstructured":"Papadaki HA, Tsatsanis C, Christoforidou A, Malliaraki N, Psyllaki M, Pontikoglou C, Miliaki M, Margioris AN, Eliopoulos GD (2004) Alendronate reduces serum TNFalpha and IL-1beta, increases neutrophil counts, and improves bone mineral density and bone metabolism indices in patients with chronic idiopathic neutropenia (CIN)-associated osteopenia\/osteoporosis. J Bone Miner Metab 22:577\u2013587","journal-title":"J Bone Miner Metab"},{"key":"55_CR33","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/jbmr.5650051005","volume":"5","author":"MG Cecchini","year":"1990","unstructured":"Cecchini MG, Fleisch H (1990) Bisphosphonates in\u00a0vitro specifically inhibit, among the hematopoietic series, the development of the mouse mononuclear phagocyte lineage. J Bone Miner Res 5:1019\u20131027","journal-title":"J Bone Miner Res"},{"key":"55_CR34","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF02556715","volume":"38","author":"PH Stevenson","year":"1986","unstructured":"Stevenson PH, Stevenson JR (1986) Cytotoxic and migration inhibitory effects of bisphosphonates on macrophages. Calcif Tissue Int 38:227\u2013233","journal-title":"Calcif Tissue Int"},{"key":"55_CR35","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1023\/A:1016281608773","volume":"12","author":"N Pennanen","year":"1995","unstructured":"Pennanen N, Lapinjpli S, Urtti A, Monkkonen J (1995) Effect of liposomal and free bisphosphonates on the IL-1\u03b2, IL-6 and TNF\u03b1 secretion from RAW 264 cells in\u00a0vitro. Pharmacol Res 12:916\u2013922","journal-title":"Pharmacol Res"},{"key":"55_CR36","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/art.1780231018","volume":"23","author":"OL Bijvoet","year":"1980","unstructured":"Bijvoet OL, Frijlink WB, Jie K, van der Linden H, Meijer CJ, Mulder H, van Paasen HC, Reitsma PH, te Velde J, de Vries E, van der Wey JP (1980) APD in Paget\u2019s disease of bone. Role of the mononuclear phagocyte system? Arthritis Rheum 23:1193\u20131204","journal-title":"Arthritis Rheum"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-009-0055-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00774-009-0055-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-009-0055-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T14:44:29Z","timestamp":1739025869000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00774-009-0055-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,20]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["55"],"URL":"https:\/\/doi.org\/10.1007\/s00774-009-0055-9","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,20]]}}}